MindWalk (HYFT) is shedding low-margin CRO roots to become a Bio-Native AI drug-discovery platform—high execution risk, but asymmetric upside if LENSai SaaS and GLP‑1 assets hit.
Overview
MindWalk Holdings (NASDAQ: HYFT), formerly ImmunoPrecise Antibodies (IPA), is undergoing a fundamental strategic metamorphosis from a high-end antibody CRO into a technology-centric TechBio platform. The rebrand and ticker change underscore the focus on LENSai™, a proprietary Bio-Native AI system that combines computational prediction with in-house wet-lab validation in a closed loop. The decisive step in this pivot was the Q2 FY2026 divestiture of the Netherlands subsidiary for roughly $12M USD (about $16.1M CAD net), which both extended cash runway and structurally improved profitability—gross margin expanded to ~65% as lower-margin services were removed. Going forward, MindWalk is concentrating on (1) SaaS licensing of LENSai to pharma partners (recurring ARR), (2) internal therapeutic asset generation for out-licensing (e.g., GLP-1, Dengue/Influenza), and (3) strategic research collaborations that generate proprietary data to improve the models. The opportunity is asymmetric: a revenue-generating lab foundation provides some downside support, while successful SaaS adoption and asset monetization could materially re-rate the business.